BioStem Technologies, Inc. (NasdaqCM: BSEM)
Health Care · Pharmaceuticals · US
$3.54
+10.28% today · -39.0% 1Y
BioStem Technologies, Inc. (NasdaqCM: BSEM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $63.19M and employs 73 people.
Over the last twelve months the share price has lost 39.0%, trading between 2.25 and 8.40.
Tweenvest scores BioStem Technologies, Inc. across four factors: quality 63/100, value 58/100, growth 100/100. Its strongest factor is growth.
BSEM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $63.19M
- Revenue (TTM)
- $34.59M
- P/E
- —
- EPS
- -1.67
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- $8.40
- 52-week low
- $2.25
- Avg volume (3M)
- —
- Shares outstanding
- 17.85M
- Employees
- 73
- Next earnings
- —
About BioStem Technologies, Inc.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
- ISIN
- US0906842002
- Founded
- 2006
- Listed since
- Mar 17, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,256.27 | +0.75% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.69 | -0.13% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $153.63 | +1.97% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.60 | +0.86% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £123.85 | +2.27% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.45 | +1.72% |
Figures last refreshed Aug 18, 2026.